342 476
[19]
Ahmed HU, EmbertonM. Benchmarks for success in focal therapy of prostate cancer: cure or control? World J Urol 2010;28:577–82.
[20]
Eggener S, Salomon G, Scardino PT, De la Rosette J, Polascik TJ, Brewster S. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol 2010;58:57–64.
[21]
Ficarra V, Novara G, Rosen RC, et al. Systematic review and meta- analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 2012;62:405–17.
[22]
Pokorny M, Novara G, Geurts N, et al. Robot-assisted simple prostatectomy for treatment of lower urinary tract symptoms secondary to benign prostatic enlargement: surgical technique and outcomes in a high-volume robotic centre. Eur Urol 2015; 68:451–7.
[23]
Donaldson IA, Alonzi R, Barratt D, et al. Focal therapy: patients, interventions, and outcomes–a report from a consensus meeting. Eur Urol 2015;67:771–7.
[24]
O’Neil LM, Walsh S, Cohen RJ, Lee S. Prostate carcinoma with positive margins at radical prostatectomy: role of tumour zonal origin in biochemical recurrence. BJU Int 2015;116(Suppl 3):42–8.
[25]
Mygatt J, Sesterhenn I, Rosner I, et al. Anterior tumors of the prostate: clinicopathological features and outcomes. Prostate Cancer Prostatic Dis 2014;17:75–80.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 3 3 – 3 4 2
342